Create Account
Sign In
Dark
chart
exchange
Terminal
Screener
Stocks
Crypto
Forex
Watchlists
Trends

PGEN
Precigen Inc
stock NASDAQ

At Close
1/27/2023 3:59:45 PM EST
1.64USD+1.235%(+0.02)4,320,856
1.63Bid   1.64Ask   0.01Spread IEX
Pre-market
1/27/2023 9:27:30 AM EST
1.63USD+0.617%(+0.01)0
After-hours
1/27/2023 4:01:30 PM EST
1.64USD0.000%(0.00)0
OverviewOption ChainHistoricalExchange VolumeShort VolumeBorrow FeeFailure to DeliverTrendsNewsMore
open chart   
open chart   
Market Cap
341.366M
Headquarters
Germantown, Maryland, USA
Industry
Biotechnology
Next Earnings
2023-02-28 (31d)
PGEN Stats
Avg. Vol. 10 Day
3,204,837
Avg. Vol. 30 Day
1,694,575
Employees
456
Market Cap
341,366,034
Shares Out.
208,150,021
P/E Ratio
13.49
EPS (ttm)
0.127
On/Off Exchange
60%/40%
6 Month Beta
2.07
1 Year Beta
1.75
2 Year Beta
1.62
3 Year Beta
1.56
52 Week Low
1.12
52 Week High
2.90
SMA50
1.66
SMA200
1.92
1 Week
-17.59%
1 Month
+24.24%
3 Month
+1.86%
6 Month
+1.86%
1 Year
-33.33%
2 Year
-80.55%
5 Year
-88.36%
Jan 12, 2022
04:32PM EST  Precigen Announced Enrollment Completion For Dose Level 3 Of Lymphodepletion Cohort, Provides Pipeline Update At J.P. Morgan Health Conference   Benzinga
04:30PM EST  Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan   PR Newswire
Jan 5, 2022
04:05PM EST  Precigen to Present at the 40th Annual J.P. Morgan Healthcare Conference   PR Newswire
Dec 14, 2021
08:08AM EST  Precigen Reveals Early Data From CAR-T Candidate In Blood Cancer Patients   Benzinga
Dec 13, 2021
05:06PM EST  Precigen Reports Interim Phase 1 Data For PRGN-3006 Ultra CAR-T In Relapsed, Refractory Acute Myeloid Leukemia: 'single administration of UltraCAR-T cells following overnight manufacturing demonstrated robust expansion, persistence in blood and bone marro   Benzinga
More News
Profile
Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The Company's technologies enable to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.

PGEN Stock Summary

Precigen Inc (NASDAQ:PGEN) stock price today is $1.64, and today's volume is 4,320,856. PGEN is up 1.235% today. The 30 day average volume is 1,694,575. PGEN market cap is 341.366M with 208,150,021 shares outstanding.



Share
About
Symbol List

Pricing
Disclaimer

ChartExchange on Twitter
ChartExchange on Reddit
© 2020 - 2023 ChartExchange LLC